To investigate the effect of metformin on pregnancy complications and pregnancy outcome in the II. and III. trimester of pregnancy in women with polycystic ovary syndrome.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
257
Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
Ålesund Hospital
Ålesund, Norway
University hospital of Bergen
Bergen, Norway
Central Hospital of Northern Norway
Bodø, Norway
Buskerud Hospital
Drammen, Norway
Gestational diabetes
Time frame: up to delivery
incidence of metabolic syndrome and neurophysiologic parameters in offspring
Time frame: Within 18 years
Preterm delivery
Time frame: up to delivery
pre-eclampsia
Time frame: up to delivery
emesis and hyperemesis
Time frame: up to delivery
Breastfeeding
Time frame: One year post partum
weight change
Time frame: up to delivery
blood pressure change
Time frame: up to delivery
Incident of instrumental deliveries
Time frame: at delivery
Hormone levels in mother and offspring
Time frame: up to delivery
Snoring and sleep quality
Time frame: up to delivery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Haugesund Hospital
Haugesund, Norway
Ringerike Hospital
Hønefoss, Norway
Elvebredden Gynekologpraksis
Kristiansand, Norway
Lillehammer Hospital
Lillehammer, Norway
Stavanger University Hospital
Stavanger, Norway
Departments of Obstetrics and Gynecology and Endocrinology, St. Olav's Hospital
Trondheim, Norway